Solana (HSDT) Expected to Announce Earnings on Thursday

Solana (NASDAQ:HSDT) is projected to post its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Solana to post earnings of ($0.34) per share and revenue of $3.40 million for the quarter. Interested persons can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 19, 2026 at 4:00 PM ET.

Solana (NASDAQ:HSDT) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of ($26.50) by $30.75. The business had revenue of $5.23 million during the quarter, compared to the consensus estimate of $0.14 million. Solana had a negative return on equity of 104.96% and a negative net margin of 679.54%. On average, analysts expect Solana to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Solana Stock Up 1.9%

HSDT stock opened at $2.16 on Tuesday. The company has a market cap of $118.56 million, a PE ratio of 0.00 and a beta of 1.06. The business has a 50-day simple moving average of $2.03 and a 200 day simple moving average of $3.27. Solana has a 52 week low of $1.59 and a 52 week high of $258.50.

Analyst Ratings Changes

A number of brokerages have recently commented on HSDT. Zacks Research raised Solana to a “hold” rating in a research note on Monday, April 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of Solana in a research note on Tuesday, April 21st. Maxim Group assumed coverage on Solana in a research note on Monday, April 6th. They set a “buy” rating and a $4.00 price target on the stock. Finally, B. Riley Financial initiated coverage on Solana in a research report on Thursday, April 23rd. They set a “buy” rating and a $3.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $3.50.

Institutional Trading of Solana

A number of hedge funds have recently made changes to their positions in HSDT. Price T Rowe Associates Inc. MD bought a new stake in Solana in the 4th quarter worth $46,000. OMERS ADMINISTRATION Corp bought a new stake in Solana in the 4th quarter worth $88,000. Aristides Capital LLC bought a new stake in Solana in the 4th quarter worth $137,000. XTX Topco Ltd bought a new stake in shares of Solana in the fourth quarter worth about $140,000. Finally, Marshall Wace LLP bought a new stake in shares of Solana in the fourth quarter worth about $195,000. 18.63% of the stock is owned by institutional investors.

Solana Company Profile

Helius Medical Technologies, Inc (NASDAQ: HSDT) is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.